| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-071 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于公司股东拟解散清算并办理公司股份非交易过 户的提示性的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 因上海阿拉丁生化科技股份有限公司（以下简称"公司"）的员工持股 平台上海晶真文化艺术发展中心（有限合伙）（以下简称"晶真文化"）拟解散 清算，晶真文化拟通过证券非交易过户的方式登记至晶真文化各合伙人名下。 截至本公告披露日，晶真文化持有公司股份为 7,381,190 股，占公司总 股本 2.22%，股东晶真文化的执行事务合伙人为公司控股股东、实际控制人招立 萍女士，公司董事/监事/高管/核心技术人员赵新安、顾玮彧、王坤、沈鸿浩、 姜苏、马亭、赵悦、凌青、海龙为晶真文化的有限合伙人。 本次非交易过户完成后，晶真文化将不再持有公司股份，本次非交易过 户不会导致公司控制权发生变更，亦不会 ...

信息披露义务人二：招立萍 上海阿拉丁生化科技股份有限公司 简式权益变动报告书 上市公司名称:上海阿拉丁生化科技股份有限公司 股票代码：688179 信息披露义务人一：徐久振 住所及通讯地址：上海市*** 住所及通讯地址：上海市*** 信息披露义务人三：上海晶真文化艺术发展中心（有限合伙） 注册地址：中国（上海）自由贸易试验区临港新片区新四平公路 468 弄 14 幢 17 号 信息披露义务人四：上海仕创供应链有限公司 注册地址：上海市奉贤区南桥镇环城西路 477 号 1 层 权益变动性质：减少（非交易过户） 签署日期：2025 年 11 月 11 日 1 上市地点：上海证券交易所 股票简称：阿拉丁 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购办法》"）、《公开发行证券的公司信 息披露内容与格式准则第 15 号——权益变动报告书》（以下简称"《准则 15 号》"） 及相关的法律、法规和规范性文件编写本报告书。 | | | 第一节 释义 除非另有说明，以下简称在本报告书中作如下释义： 二、信息披露义务人签署本报告书已获得 ...

阿拉丁公告，控股股东、实际控制人招立萍女士控制的企业上海晶真文化艺术发展中心（有限合伙）拟 解散清算，通过证券非交易过户方式登记至各合伙人名下，导致控股股东、实际控制人及一致行动人合 计持有公司股份比例减少。权益变动前，控股股东、实际控制人及一致行动人合计持股比例为 46.27%；权益变动后，持股比例减少至44.76%。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 一、交易概述 ● 上海阿拉丁生化科技股份有限公司（以下简称"阿拉丁"或"公司"）全资子公司上海客学谷网络科技有 限公司（以下简称"客学谷"）拟以自有或自筹资金按比例购买喀斯玛（北京）科技有限公司（以下简 称"喀斯玛科技"）员工持股平台嘉兴科服投资合伙企业（有限合伙）（以下简称"嘉兴科服"）全体合伙 人分别持有的嘉兴科服40%的财产份额，按比例购买嘉兴科服间接合伙人嘉兴科旺企业管理咨询合伙企 业（有限合伙）（以下简称"嘉兴科旺"）的全体合伙人分别持有的嘉兴科旺40%财产份额；拟以自有或 自筹资金按比例购买喀斯玛科技员工持股平台嘉兴科进企业管理咨询合伙企业（有限合伙）（以下简 称"嘉兴科进"）的全体合伙人分别持有的嘉兴科进40%财产份额。具体内容详见公司于2025年10月30日 在上海证券交易所网站(www.sse.com.cn)披露的《上海阿拉丁生化科技股份有限公司关于全资子公司收 购控股孙公司持股平台财产份额的公告》（公告编 ...

证券日报网讯 11月10日晚间，阿拉丁发布公告称，公司全资子公司上海客学谷网络科技有限公司拟以 自有或自筹资金按比例购买喀斯玛（北京）科技有限公司（简称"喀斯玛科技"）员工持股平台嘉兴科服 投资合伙企业（有限合伙）（简称"嘉兴科服"）全体合伙人分别持有的嘉兴科服40%的财产份额，按比 例购买嘉兴科服间接合伙人嘉兴科旺企业管理咨询合伙企业（有限合伙）（简称"嘉兴科旺"）的全体合 伙人分别持有的嘉兴科旺40%财产份额；拟以自有或自筹资金按比例购买喀斯玛科技员工持股平台嘉兴 科进企业管理咨询合伙企业（有限合伙）（简称"嘉兴科进"）的全体合伙人分别持有的嘉兴科进40%财 产份额。近日，嘉兴科服和嘉兴科旺已完成工商登记手续。 （编辑 任世碧） ...

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-070 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于全资子公司收购控股孙公司持股平台财产份额 的进展暨部分完成工商登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、交易概述 上海阿拉丁生化科技股份有限公司（以下简称"阿拉丁"或"公司"） 全资子公司上海客学谷网络科技有限公司（以下简称"客学谷"）拟以自有或自 筹资金按比例购买喀斯玛（北京）科技有限公司（以下简称"喀斯玛科技"）员 工持股平台嘉兴科服投资合伙企业（有限合伙）（以下简称"嘉兴科服"）全体 合伙人分别持有的嘉兴科服 40%的财产份额，按比例购买嘉兴科服间接合伙人嘉 兴科旺企业管理咨询合伙企业（有限合伙）（以下简称"嘉兴科旺"）的全体合 伙人分别持有的嘉兴科旺 40%财产份额；拟以自有或自筹资金按比例购买喀斯玛 科技员工持股平台嘉兴科进企业管理咨询合伙企业（有限合伙）（以下简称"嘉 ...

Core Points - Aladdin's stock price increased by 2.07% on November 10, reaching 13.31 CNY per share, with a total market capitalization of 4.427 billion CNY [1] - The company reported a year-to-date stock price increase of 17.44%, with a recent 5-day increase of 3.26% and a 60-day decrease of 11.27% [1] - Aladdin's main business involves the research, production, and sales of reagents, with 96.96% of revenue coming from scientific reagents [1] Financial Performance - For the period from January to September 2025, Aladdin achieved operating revenue of 444 million CNY, representing a year-on-year growth of 17.59% [2] - The net profit attributable to the parent company was 57.76 million CNY, showing a year-on-year decrease of 20.41% [2] Shareholder Information - As of September 30, 2025, the number of Aladdin's shareholders decreased by 7.17% to 11,600, while the average circulating shares per person increased by 7.72% to 28,729 shares [2] - Since its A-share listing, Aladdin has distributed a total of 241 million CNY in dividends, with 150 million CNY distributed in the last three years [3] - Notably, some institutional investors exited the top ten circulating shareholders list as of September 30, 2025 [3]

Core Viewpoint - Aladdin (688179) has seen a net financing inflow of 5.06 million yuan on November 5, 2025, with a total financing balance of 199 million yuan, indicating a positive trend in investor sentiment towards the stock [1][4]. Financing Summary - On November 5, 2025, the financing buy-in was 9.1222 million yuan, while financing repayment was 9.0716 million yuan, resulting in a net buy of 5.06 million yuan [1]. - The financing balance reached 199 million yuan, with a 0.03% increase from the previous day [4]. - Over the past three trading days, the cumulative net buy amounted to 10.1071 million yuan, with 11 out of the last 20 trading days showing net financing inflows [1]. Margin Trading Summary - On November 5, 2025, there were 1,400 shares sold short, with 400 shares repaid, resulting in a net short sale of 1,000 shares [2][3]. - The margin balance on November 5 was 18,500 yuan, with a total of 1,447 shares remaining available for short selling [3]. Margin Trading Balance Changes - The margin trading balance on November 5 was 199 million yuan, reflecting a 0.03% increase from the previous day [4]. - The margin trading balance had previously increased by 8.0388 million yuan on November 4, 2025, marking a 4.20% rise [4].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report emphasizes the ongoing progress of centralized procurement and medical insurance negotiations, highlighting investment opportunities in the pharmaceutical sector [5][6] - The report notes that the 2025 National Medical Insurance negotiations have commenced, with a focus on the commercialization potential of drugs included in the insurance list [6][19] - The pharmaceutical sector has shown resilience, with a 1.31% increase in October's fifth week, outperforming the CSI 300 index by 1.74 percentage points [7][22] Summary by Sections Section 1: Centralized Procurement and Medical Insurance Negotiations - The latest round of centralized procurement has been optimized, achieving a selection rate of 57% for the 11th batch, involving 55 products and 445 companies [5][15] - The 2025 medical insurance negotiations are expected to last 4-5 days, with 535 drug names passing the preliminary review for the basic medical insurance directory [6][19] Section 2: Market Performance - In the fifth week of October, the pharmaceutical sector rose by 1.31%, ranking 9th among 31 sub-industries [7][22] - The vaccine sector experienced the highest increase of 3.38%, while the medical consumables sector saw the largest decline of 1.98% [28] Section 3: Stock Recommendations - Monthly stock recommendations include companies such as Sanofi, Innovent Biologics, and WuXi Biologics [8] - Weekly stock recommendations feature companies like Kelun Pharmaceutical and Huadong Medicine [8]

Core Viewpoint - Aladdin's stock price increased by 4.21% to 12.87 yuan as of October 30, 2025, with a trading volume of 171,200 shares and a turnover of 221 million yuan [1] Trading Information Summary - On October 30, 2025, the net outflow of main funds was 19.755 million yuan, accounting for 8.93% of the total turnover; retail investors had a net inflow of 18.9297 million yuan, representing 8.56% of the total turnover [2] Shareholder Changes - As of September 30, 2025, the number of shareholders decreased to 11,600, a reduction of 894, or 7.17% from June 30, 2025; the average number of shares held per account increased from 26,700 to 28,700, with an average market value of 374,400 yuan [3] Financial Performance Highlights - Aladdin's Q3 2025 report indicated a total revenue of 444.4 million yuan for the first three quarters, a year-on-year increase of 17.59%; net profit attributable to shareholders was 57.76 million yuan, down 20.41% year-on-year; Q3 alone saw a revenue of 169 million yuan, up 21.26% year-on-year, and a net profit of 29.30 million yuan, up 15.8% year-on-year [4][6] Company Announcements - Aladdin plans to acquire a 55.97% stake in Kasma Technology through a transaction valued at 133.16 million yuan [5] Key Financial Data - For Q3 2025, the net cash flow from operating activities was 159 million yuan, a significant increase of 142.25% year-on-year, primarily due to the inclusion of Kasma Holdings in the consolidated financial statements [6][7] - Total assets as of September 30, 2025, reached 2.58 billion yuan, a 45.13% increase from the end of the previous year, largely due to the acquisition of Kasma Holdings [7] Shareholder Information - The top ten shareholders include Xu Jiuzhen with 27.72% and Zhao Liping with 14.85% of shares; Xu and Zhao are married, and their company, Shanghai Shichuang Supply Chain Co., Ltd., is controlled by them [8][9]